Introduction
Methods
Protocol and Registration
Eligibility Criteria
Search
Study Selection
Data Collection Process
Data Items
Risk of Bias in Individual Studies
Summary Measures
Synthesis of Results
Risk of Bias Across Studies
Additional Analyses
Results
Study Selection
Authors | Operation period | Location | N | Follow-up (months) | Age (years; mean/range) | Operative technique details | Design | Included for |
---|---|---|---|---|---|---|---|---|
Studies on LAGB | ||||||||
Abu-Abeid et al. [27] | NR | Tel-Aviv, Israel | 11 | 6–36 | 15.7 | Perigastric | Retrospective | M – CO – CM |
Al-Qahtani [28] | Jan, 2003–12/2005 | Riyadh, Saudi Arabia | 51 | 3–34 | 16.8 | Pars flaccida | Retrospective | CM |
Alqahtani [29] | 6/2004–12/2007 | Riyadh, Saudi Arabia | 50 | NR–60 | 17 | Pars flaccida | Retrospective | CO |
Angrisani et al. [30] | 1/1996–12/2003 | Naples, Italy | 58 | 0–84 | 18.0 | 55 perigastric; 3 pars flaccida | Retrospective | M – CO – CM |
Dolan et al. [31] | 1996–NR | Brisbane, Australia—Royal Brisbane Hospital | 17 | 12–46 | 16.7 | Since 1999 pars flaccida | Prospective | M |
Fielding et al. [32] | 1998–2003 | Brisbane, Australia—Wesley Hospital | 41 | 1–70 | 15.6 | Since 1999 pars flaccida | Retrospective | CO – CM |
Holterman et al. [14] | 3/2005–6/2007 | Chicago, IL, USA | 20 | 15–42 | 16 | Perigastric | Prospective | M – CO – CM – QOL |
Inge et al. [33] | 2/2007–12/2011 | Five centers, USA | 14 | 1 | 17.1 | Pars flaccida | Prospective | CO |
Lee et al. [34] | 2002–2011 | New York, NY, USA—St. Luke’s-Roosevelt Hospital Center | 23 | 1–24 | 17.2 | Pars flaccida | Retrospective | CO – CM |
Lennerz et al. [35] | 1/2005–12/2010 | 23 centers, Germany | 10 | 0 to >30 | 16.7 | NA | Prospective | M |
Messiah et al. [36] | 4/2004–10/2010 | 360 facilities, USA | 436 | 0–12 | 18.5 | NA | Prospective database | CM |
Nadler et al. [37] | 9/2001–1/2007 | New York, NY, USA—NY University School of Medicine | 73 | 12–24 | 15.8 | Pars flaccida | Prospective | M – CO – CM |
O’Brien et al. [15] | 5/2005–9/2008 | Melbourne, Australia | 25 | 24 | 16.5 | Pars flaccida | RCT | M – CO – QOL |
Silberhumer et al. [17] | 1998–2004 | Salzburg/Vienna, Austria | 50 | 63–138 | 17.1 | Pars flaccida | Retrospective multicenter | M – CO – CM – QOL |
Silva et al. [38] | 7/2001–6/2010 | Oporto, Portugal | 14 | 12–36 | 16.3 | Pars flaccida | M – CO – CM | |
Varela et al. [39] | 2002–2006 | 59 university centers, USA | 90 | 1 | 12–18 | NA | Retrospective | CO |
Yitzhak et al. [18] | 2000–2003 | Beer Sheva, Israel | 60 | 25–65 | 16 | Two pars flaccida techniques | Retrospective | M – CO – CM – QOL |
Zitsman et al. [40] | 8/2006–NR | New York, NY, USA—Columbia University Medical Center | 100 | 12 | 14–19 | Pars flaccida | NR | M – CO – CM |
Studies on RYGB | ||||||||
De la Cruz-Munoz et al. [41] | 2001–2010 | Miami, FL, USA | 71 | 9–15 | 18.3 | NR | Retrospective | M – CO |
Inge et al. [42] | 2001–2003 | Cincinnati, OH, USA | 10 | 1–24 | NR | Two open/Eight laparoscopic, hand-sewn gastrojejunostomy | Retrospective | CO – CM |
Inge et al. [33] | 2/2007–12/2011 | Five centers, USA | 161 | 1 | 17.1 | NA | Prospective | CO |
Lee et al. [34] | 2002–2011 | New York, NY, USA—St. Luke’s-Roosevelt Hospital Center | 32 | 1–24 | 18.6 | Pouch 50 mL/40-cm biliopancreatic limb, 100-cm alimentary limb | Retrospective | CO – CM |
Messiah et al. [36] | 4/2004–10/2010 | 360 facilities, USA | 454 | 12 | 18.5 | NA | Prospective database | CM |
Miyano et al. [43] | 8/2002–5/2007 | Cincinnati, OH, USA | 77 | 3 | 16.8 | Biliopancreatic limb 75–150 cm/15–30 cm from Treitz/30–45-mL pouch | Retrospective | CO – CM |
Nijhawan et al. [44] | 2001–2007 (approx.) | San Diego, CA, USA | 20 | 60–120 | 16.9 | Pouch 15 mL/Roux limb 75 cm | Retrospective | M – CO – CM |
Olbers et al. [22] | 2/2006–6/2009 | Gothenburg, Sweden | 81 | 24 | 16.5 | Pouch <20 mL/Roux limb 80 cm | Prospective | M – CO – CM – QOL |
Strauss et al. [45] | 4/1985–5/1999 | New Brunswick, NJ, USA | 10 | 8–156 | 16.2 | Pouch 20 ± 5 mL/Roux limb 50–150 cm or to distal jejunum | Retrospective | M – CO – CM |
Sugerman et al. [19] | 1981–1/2002 | Richmond, VA, USA | 33 | 1–14 | 16 | Standard, long-limb, and distal gastric bypass | Retrospective | M – CO – CM |
Varela et al. [39] | 2002–2006 | 59 university centers, USA | 191 | 1 | 12-18 | NA | Retrospective | CO |
Zeller et al. [20] | 5/2004–1/2007 | Cincinnati, OH, USA | 31 | 12 | 16.4 | Pouch 20 mL/5–10 cm from Treitz/Roux limb 100–150 cm [46] | Prospective | QOL |
Zeller et al. [21] | 5/2004–9/2005 | Cincinnati, OH, USA | 16/14 | 24 | 16.2 | Pouch 20 mL/5–10 cm from Treitz/Roux limb 100–150 cm [46] | Prospective | M – QOL |
Studies on LSG | ||||||||
Aldaqal et al. [23] | 11/2009–2/2012 | Jeddah, Saudi Arabia | 32 | 12 | 15.2 | 50–80-mL lumen | Prospective | M – CO – CM – QOL |
Alqahtani et al. [47] | 3/2006–2/2011 | Riyadh, Saudi Arabia | 99 | 6–24 | 14 | NR | Retrospective | M – CO – CM |
Boza et al. [48] | 1/2006–10/2009 | Santiago, Chile | 51 | 6–24 | 18 | 60-F calibration catheter | Retrospective | M – CO – CM |
Inge et al. [33] | 2/2007–12/2011 | Five centers, USA | 67 | 1 | 17.1 | NA | Prospective | CO |
Lennerz et al. [35] | 1/2005–12/2010 | 23 centers, Germany | 11 | 12 | 15.4 | NA | Prospective | M – CM |
Nadler et al. [49] | 1/2010–12/2011 | Washington, DC, USA | 23 | 9–15 | 17.3 | 40-F bougie | Retrospective | M – CO – CM |
Varela et al. [39] | 2002–2006 | 59 university centers, USA | 28 | 1 | 12–18 | NA | Retrospective | CO |
Risk of Bias Within Studies
Study | Inclusion and exclusion criteria | Intervention before surgery | Support after surgery | Loss to follow-up |
---|---|---|---|---|
Gastric banding | ||||
Abu-Abeid et al. [27] | NIH criteria | ≥1-year dietician | Emotional support | NR |
Al-Qahtani [28] | NIH criteria | Failure to lose weight for ≥6 months with conservative treatment | Flexible follow-up, reinforcement of the importance of diet and exercise | NR |
Alqahtani [29] | NIH criteria | Failure to lose weight for ≥6 months with conservative treatment | Flexible follow-up, reinforcement of the importance of diet and exercise | NR |
Angrisani et al. [30] | BMI ≥40 or ≥35 kg/m2 with comorbidities, psychiatric and genetic disorders excluded | ≥1 year of conservative medical treatment | NR | 8–12–24 % [12–36–60 months) |
De la Cruz-Munoz et al. [41] | NIH criteria | NR | NR | 9 % for LAGB + RYGB |
Dolan et al. [31] | NR (2/17 patients BMI < 35) | NR | NR | 0–31 % (12–24 months) |
Fielding et al. [32] | BMI ≥40 or ≥35 kg/m2 with comorbidities | “Appropriate pediatric care” | Surgeon alone | 2 % |
Holterman et al. [14] | NIH criteria | 4–6-month multidisciplinary program | Behavioral, nutritional, and activity monitoring and monthly counseling | 20 % |
Inge et al. [33] | Pratt [50], BMI ≥35 with major comorbidities and BMI ≥40 with other comorbidities, no binge-purge eating disorders | NR | NR | NR |
Lee et al. [34] | NIH criteria, procedure choice on individual basis | Exercise and diet with nutritionist, educational sessions, and psychological and nutritional evaluations | NR | 70 % (24 months) |
Lennerz et al. [35] | CAADIP 2010 and IFSO guidelines, procedure choice on individual basis | NR | Multidisciplinary approach including a pediatrician, child psychologist, surgeon, and the primary care provider | 53 % (LAGB + LSG) |
Messiah et al. [36] | NA (national database) | NA | NA | 12–3–63 % (3–6–12 months) |
Nadler et al. [37] | NIH criteria | NR | First postoperative year monthly to monitor weight loss, appetite, dysphagia, or food intolerance and eating behavior; every 3 months after the first year | 11 % |
O’Brien et al. [15] | BMI >35 kg/m2, identifiable medical complications, physical limitations, or psychosocial difficulties | >3 years of attempts to lose weight by lifestyle means | Participants were encouraged to do exercise and maintain a high level of activity | 4 % |
Silberhumer et al. [17] | >99.5th age- and gender-adjusted growing percentile, adolescents <14 years old at least one comorbidity | Diet camps, behavioral therapy, and drug therapy | 3, 6, and 12 months after surgery by a surgeon; pediatricians and psychologists on a regular basis | 10 % |
Silva et al. [38] | IPEG guidelines | NR | NR | 0 % |
Varela et al. [39] | NA (national database) | NA | NA | NA |
Yitzhak et al. [18] | NIH criteria | Failed conservative treatment | NR | 0 % |
Zitsman et al. [40] | Pratt [50], BMI ≥35 with major comorbidities and BMI ≥40 with other comorbidities, no binge-purge eating disorders | NR | Follow-up visits, no support program | 0 % |
Gastric bypass | ||||
De la Cruz-Munoz et al. [41] | NIH criteria | NR | NR | 9 % for LAGB + RYGB |
Inge et al. [42] | BMI ≥40 kg/m2 with serious obesity-related comorbidities or BMI ≥50 kg/m2 with other comorbidities | ≥6 months of organized attempts at weight management | Regular visits with the surgeon, psychologist, and dietician | NR |
Inge et al. [33] | Pratt [50], BMI ≥35 with major comorbidities and BMI ≥40 with other comorbidities; no binge-purge eating disorders | NR | NR | NR |
Lee et al. [34] | NIH criteria, procedure choice on individual basis | Exercise and diet with nutritionist, educational sessions, and psychological and nutritional evaluations | NR | 84 % (24 months) |
Messiah et al. [36] | NA (national database) | NA | NA | 12–34–63 % (3–6–12 months) |
Miyano et al. [51] | 2002–2006, BMI ≥40 kg/m2 with serious obesity-related comorbidities or BMI ≥ 50 kg/m2 with other comorbidities 2006–2007, BMI ≥35 kg/m2 with serious obesity-related comorbidities or BMI ≥40 kg/m2 with other comorbidities | ≥6 months of organized attempts at weight management | Regular visits with the surgeon, psychologist, and dietician | NR |
Nijhawan et al. [44] | NR | NR | Follow-up visits, encourage support groups | 20 % |
Olbers et al. [22] | BMI >40 or BMI >35 kg/m2 with comorbidity, pubertal Tanner stage > III and passed peak height growth velocity, no untreated psychiatric disorder | Multidisciplinary lifestyle intervention | Follow-up visits, no support program | 0 % |
Strauss et al. [45] | NR | Serious attempts at weight loss in diet and behavior modification programs | NR | 10 % |
Sugerman et al. [19] | NIH criteria | NR | NR | 3.1–6.7–22.2–33.3 % (1–5–10–14 years) |
Varela et al. [39] | NA (national database) | NA | NA | NA |
Zeller et al. [20] | Inge: BMI ≥40 with comorbidity or ≥50 [52] | Inge, ≥6 months of organized attempts at weight management | NR | 10 % (12 months) |
Zeller et al. [21] | Inge: BMI ≥40 with comorbidity or ≥50 [52] | Inge, ≥6 months of organized attempts at weight management | NR | 12 % |
Sleeve gastrectomy | ||||
Aldaqal et al. [23] | BMI ≥40 kg/m2 with serious obesity-related comorbidities or BMI ≥50 kg/m2 with other comorbidities | >6 months of recognized, medically supervised weight loss attempts | NR | NR |
Alqahtani et al. [47] | BMI ≥40 or ≥35 kg/m2 with comorbidities (five patients with BMI <35) | 6 months in a formal weight loss program | Follow-up visits | 17–14 % (12–24 months) |
Boza et al. [48] | NIH criteria, evaluation by multidisciplinary team | NR | NR | 13–17 % (12–24 months) |
Inge et al. [33] | Pratt [50], BMI ≥35 with major comorbidities and BMI ≥40 with other comorbidities, no binge-purge eating disorders | NR | NR | NR |
Lee et al. [34] | NIH criteria, procedure choice on individual basis | Exercise and diet with nutritionist, educational sessions, and psychological evaluations | NR | 70 % (24 months) |
Lennertz et al. [35] | CAADIP 2010 and IFSO guidelines, procedure choice on individual basis | NR | Multidisciplinary approach including a pediatrician, child psychologist, surgeon, and the primary care provider | 53 % (LSG + LAGB) |
Nadler et al. [49] | NIH criteria | NR | Follow-up visits, no program | 19–0 % (6–12 months) |
Oberbach et al. [53] | Inge: BMI ≥40 with comorbidity or ≥50 [52] | “Every conservative treatment had failed” | NR | NR |
Varela et al. [39] | NA (national database) | NA | NA | NA |
Results of Individual Studies
Synthesis of Results
Study | N (at FU) | FU (months) | BMI baseline | SD | BMI loss | SD |
---|---|---|---|---|---|---|
Gastric banding | ||||||
Perigastric technique | ||||||
Abu-Abeid [27] | 11 | 23 | 46.4 | NR | 14.3a
| NR |
Angrisani [30] | 37 | 36 | 46.1 | 6.31 | 9.1b
| 4.2 |
Dolan [31] | 9 | 24 | 42.6 | 6.7 | 12.3a
| 5.2 |
Holterman [14] | 12 | 18 | 50 | 10 | 9.4a
| 5.4 |
Pars flaccida technique | ||||||
Lennerz [35] | 10 | 12 | 48.1 | 9.8 | 10.1a
| 9.1 |
Nadler [37] | 47 | 12 | 47.6 | 7 | 15.2b
| 9.7 |
O’Brien [15] | 24 | 24 | 42.3 | 6.1 | 12.7a
| NR |
Silberhumer [17] | 48 | 36 | 45.2 | 7.6 | 12.7b
| 5.4 |
Silva [38] | 12 | 36 | 46.1 | 11.8 | 12.8b
| 5.2 |
Yitzhak [18] | 60 | 39.5 | 43 | NR | 13a
| NR |
Zitsman [40] | 47 | 12 | 50 (M) 48.1 (F) | NR | 6.7a
| NR |
Gastric bypass | ||||||
De la Cruz-Munoz [41] | 71 | 9-15 | 46.2 | 5.1 | 11.3b
| 5.7 |
Nijhawan [44] | 20 | 85.8 | 45.7 | NR | 17.1a
| NR |
Olbers [22] | 81 | 24 | 45.5 | 6.0 | 15.3b
| 6.0 |
Strauss [45] | 10 | 68.8 | 52.4 | 10.1 | 16.2c
| 10.3 |
Sugerman [19] | 20 | 60 | 52 | 11 | 19a
| NR |
Zeller [20] | 14 | 24 | 59.9 | 8.7 | 21.1b
| 5.1 |
Sleeve gastrectomy | ||||||
Aldaqal [23] | 32 | 12 | 49.6 | 4.9 | 20.3 | NR |
Alqahtani [47] | 76 | 6 | 49.6 (median) | 11.5 (IQR) | 14.3b
| 5.5 |
Boza [48] | 34 | 24 | 38.5 | 3.7 | 12.2a
| NR |
Lennerz [35] | 11 | 12 | 51.8 | 8.3 | 13.1a
| 8.2 |
Nadler [57] | 13 | 6 | 52 | 9 | 10.5b
| 3.8 |
Authors | N | FU | Complication | Total | Intervention | Total | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Death | Perioperative complications | Surgical site infection | Late complications | Hiatal hernia | Band-specific | Gastrointestinal complaints | Nutritional deficiency / dehydration | DVT | Pulmonary system (pneumonia, pulmonary embolism) | Conversion to malabsorptive anatomy | Band, removal | Band replacement/repositioning | Band, port revision | Gastrointestinal obstruction | Leak/fistula repair | Cholecystectomy | Abdominal hernia repair | EGD | |||||
LAGB | |||||||||||||||||||||||
Perigastric | |||||||||||||||||||||||
Abu-Abeid et al. | 11 | 6–36 months | * | 0 | * | 0 | * | 0 | 0 | * | * | * | 0 | * | * | * | * | * | * | * | * | * | 0 |
Angrisani et al. | 58 | 0–7 years | 0 | 1 | * | * | * | 6 | * | * | * | * | 7 | 3 | 5 | 3 | * | * | * | * | * | * | 11 |
Holterman et al. | 20 | 15–42 months | * | * | * | * | 1 | 4 | * | * | * | * | 5 | * | * | 1 | 3 | * | * | * | 1 | * | 5 |
Pars flaccida | |||||||||||||||||||||||
Alqahtani | 50 | NR–5 years | * | 0 | * | * | * | 2 | 9 | 1 | * | * | 12 | * | 2 | * | * | * | * | * | 0 | * | 2 |
Fielding et al. | 41 | 1–70 months | 0 | 0 | * | * | * | 2 | * | * | * | * | 2 | * | * | 1 | 1 | * | * | * | * | * | 2 |
Lee et al. | 23 | 1–24 months | * | * | * | * | * | 2 | * | * | * | * | 2 | * | 1 | 1 | * | * | * | * | * | * | 2 |
Nadler et al. | 73 | 12–24 months | 0 | * | 1 | 1 | 3 | 7 | 5 | * | * | * | 17 | * | 2 | 5 | 1 | * | * | 1 | 3 | * | 12 |
O’Brien et al. | 24 | 24 months | * | 0 | * | * | * | 8 | 1 | * | * | * | 9 | * | * | 6 | 2 | * | * | 1 | * | * | 9 |
Silberhumer et al. | 50 | 63–138 months | * | * | * | * | * | 6 | * | * | * | * | 6 | 8 | * | 2 | 2 | * | * | * | * | * | 12 |
Silva et al. | 14 | 12–36 months | 0 | 0 | * | * | * | 2 | 2 | * | * | * | 4 | * | * | * | 2 | * | * | 1 | * | * | 3 |
Yitzhak et al. | 60 | 25–65 months | 0 | 0 | * | * | * | 10 | * | * | * | * | 10 | * | 2 | 6 | 2 | * | * | * | * | * | 10 |
Zitsman et al. | 100 | 12 months | 0 | 1 | * | 1 | 1 | 6 | * | * | * | * | 9 | * | * | 3 | 3 | 2 | * | * | 1 | * | 9 |
Inge et al. | 14 | 30 days | 0† | 1 | 0† | 0† | *† | *† | 1† | *† | 0† | 1† | 3† | * | * | * | * | 0 | * | * | 0 | * | 0† |
TOTAL | 538 | 0 % (0/346) | 0.8 % (3/372) | 1.4 % (1/73) | 1.1 % (2/184) | 2.6 % (5/193) | 10.5 % (55/524) | 9.9 % (17/172) | 2 % (1/50) | * | * | 83 | 11 | 12 | 28 | 16 | 2 | 0 | 3 | 5 | 0 | 14.7 % (77/524) | |
Short-term perioperative outcome | |||||||||||||||||||||||
Varela et al. | 90 | 30 days | 0 | * | * | * | * | * | * | * | * | * | 0 | * | * | * | * | * | * | * | * | * | 0 |
RYGB | |||||||||||||||||||||||
De la Cruz-Munoz et al. | 71 | 9–1 months | * | 0 | * | * | * | * | 2 | * | * | * | 2 | * | * | * | * | * | * | * | * | * | 0 |
Inge et al. | 10 | 1 month–2 years | * | 1 | * | 3 | * | * | 1 | 1 | 1 | * | 7 | * | * | * | * | * | 1 | * | * | 1 | 2 |
Lee et al. | 32 | 1–24 months | * | * | * | 1 | * | * | * | 1 | * | * | 2 | * | * | * | * | * | 1 | * | * | * | 1 |
Miyano et al. | 77 | 90 days | 0 | 2 | 2 | 24 | * | * | * | 5 | 1 | 0 | 34 | * | * | * | * | 4 | 4 | * | 2 | 13 | 23 |
Nijhawan et al. | 20 | 60–120 months | 0 | 0 | 1 | 3 | * | * | * | * | * | 1 | 5 | * | * | * | * | 2 | 0 | * | * | 1 | 3 |
Olbers et al. | 81 | 24 months | 0 | 2 | * | 6 | * | * | 11 | * | * | * | 19 | * | * | * | * | 5 | 0 | 5 | 2 | * | 12 |
Strauss et al. | 10 | 8–156 months | * | 0 | * | 2 | * | * | 2 | 1 | * | * | 5 | * | * | * | * | 1 | * | 2 | 1 | * | 4 |
Sugerman et al. | 33 | 1–14 years | 2 | * | 5 | 14 | * | * | * | 1 | * | 1 | 22 | 2 | * | * | * | 1 | * | * | 6 | 3 | 12 |
Inge et al. | 161 | 30 days | 0† | 17 | 3† | 9† | *† | *† | *† | *† | 1† | 2† | 17† | * | * | * | * | 3 | 4 | * | * | 3 | 10† |
TOTAL | 495 | 0.9 % (2/211) | 5.1 % (22/430) | 6.2 % (8/130) | 20.2 % (53/263) | * | * | 9.3 % (16/172) | 5.6 % (9/162) | 2.3 % (2/87) | 1.5 % (2/130) | 96 | 2 | 0 | 0 | 0 | 13 | 6 | 7 | 11 | 18 | 17.1 % (57/334) | |
Short-term perioperative outcome | |||||||||||||||||||||||
Varela et al. | 191 | 30 days | 0 | * | * | * | * | * | * | * | * | * | 4.3–7.6 % | * | * | * | * | * | * | * | * | * | 0 |
LSG | |||||||||||||||||||||||
Aldaqal et al. | 32 | 12 months | * | 0 | * | * | * | * | * | * | * | * | 0 | * | * | * | * | * | * | * | * | * | 0 |
Alqahtani et al. | 99 | 6–24 months | 0 | 0 | 2 | 1 | * | * | 3 | * | * | * | 6 | * | * | * | * | * | * | * | * | * | 0 |
Boza et al. | 51 | 6–24 months | 0 | 0 | * | 1 | * | * | * | * | * | * | 1 | * | * | * | * | * | 1 | * | * | 1 | 2 |
Nadler et al. | 23 | 9–15 months | * | 0 | * | 0 | * | * | 3 | * | * | * | 3 | * | * | * | * | * | * | * | * | * | 0 |
Inge et al. | 67 | 30 days | 0† | 2 | 2† | 3† | *† | *† | 2† | 1† | 0† | 1† | 11† | * | * | * | * | 0 | 2 | * | 0 | * | 2† |
TOTAL | 272 | 0 % (0/150) | 0.7 % (2/272) | 2.0 % (2/99) | 1.2 % (2/173) | * | * | 4.9 % (6/122) | * | * | * | 10 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1.0 % (2/205) | |
Short-term perioperative outcome | |||||||||||||||||||||||
Varela et al. | 28 | 30 days | 0 | * | * | * | * | * | * | * | * | * | 0 | * | * | * | * | * | * | * | * | * | 0 |
Author | HT | Dyslipidemia | T2DM | Prediabetes/Insulin resistance | OSAS | Musculoskeletal complaints | Asthma | Menstrual problems | GERD | |
---|---|---|---|---|---|---|---|---|---|---|
LAGB | ||||||||||
Abu-Abeid et al. [27] | Baseline N (%) | NR | 2/11 (18.2 %)†, 1/11 (9.1 %)‡ | NR | NR | NR | NR | NR | 2/11 (18.2 %)‡ | NR |
Resolved N (%) | NR | 2/2 (100 %)†, 0/1 (0 %)‡ | NR | NR | NR | NR | NR | 2/2 (100 %)‡ | NR | |
Al-Qahtani et al. [28] | Baseline N (%) | 6/51 (11.8 %) | NR | 7/51 (13.7 %) | NR | 10/51 (19.6 %) | 7/51 (13.7 %)† | NR | NR | NR |
Resolved, N (%) | 6/6 (100 %) | NR | 7/7 (100 %) | NR | 10/10 (100 %) | 7/7 (100 %)† | NR | NR | NR | |
Angrisani [30] | Baseline N (%) | 8/58 (13.4 %) | 6/58 (10.3 %) | 8/58 (13.4 %) | NR | 10/58 (17.2 %) | 12/58 (20.7 %)† | NR | 4/58 (69 %)‡ | NR |
Resolved N (%) | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
Fielding et al. [32] | Baseline N (%) | 2/41 (4.9 %) | NR | 2/41 (4.9 %) | NR | 1/41 (2.4 %) | 1/41 (2.4 %)‡ | NR | NR | NR |
Resolved N (%) | 2/2 (100 %) | NR | 2/2 (100 %) | NR | 1/1 (100 %) | 1/1 (100 %)‡ | NR | NR | NR | |
Holterman et al. [14] | Baseline N (%) | 9/20 (45 %) | 16/20 (80 %) | NR | 18/20 (90 %)† | NR | NR | NR | NR | NR |
Resolved N (%) | 9/9 (100 %) | 11/16 (67 %) | NR | 13/18 (72 %)† | NR | NR | NR | NR | NR | |
Lee et al. [34] | Baseline N (%) | 2/23 (9 %) | 2/23 (9 %)‡ | 0/23 (0 %) | NR | 3/23 (13 %) | NR | NR | NR | NR |
Resolved N (%) | NR | 1/2 (50 %) | 0/0 | NR | NR | NR | NR | NR | NR | |
Messiah et al. [36] | Baseline N (%) | 80 (18 %) | 61 (14 %) | 65 (15 %) | NR | 80 (18 %) | 113 (25 %)¥; 90 (21 %) # | 84 (19 %) | 50 (11 %) †;45 (10 %) ¥ | 109 (25 %) |
Improved N (%) | 54 % | 23 % | 59 % | NR | 46 % | 50 % ¥44 % # | 23 % | 38 % †31 % ¥ | 45 % | |
Nadler et al. [37] | Baseline N (%) | 4/21 (19 %) | 7/21 (33 %) | NR | 5/21 (24 %)◊ | 4/21 (19 %) | 10/21 (48 %)¥, 5/21 (24 %)† | NR | NR | 1/ 21 (5 %) |
Resolved N (%) | 4/4 (100 %) | 3/7 (43 %) | NR | 5/5 (100 %)◊ | 3/4 (75 %) | 7/10 (70 %)¥, 3/5 (60 %)† | NR | NR | 1/1 (100 %) | |
Silberhumer et al. [17] | Baseline N (%) | 12/50 (24 %) | 4/50(8 %) | 5/50 (10 %) | NR | NR | 8/50 (16 %)§ | 3/50 (6 %) | NR | 1/50 (2 %) |
Resolved, N (%) | 11/12 (91.7 %) | 4/4 (100 %) | 5/5 (100 %) | NR | NR | 7/8 (87.5 %)§ | 3/3 (100 %) | NR | 1/1 (100 %) | |
Silva et al. [38] | Baseline N (%) | 13/14 (92 %) | 12/14 (85.7 %) | NR | 13 /14 (92.8 %)† | NR | NR | NR | NR | NR |
Resolved, N (%) | 13/13 (100 %) | 8/12 (66.7 %) | NR | 13/13 (100 %)† | NR | NR | NR | NR | NR | |
Yitzhak et al. [18] | Baseline N (%) | 3/60 (5 %) | NR | 2/60 (33.3 %) | NR | 10/60 (16.7 %) | NR | 3/60 (%) | NR | NR |
Resolved, N (%) | 3/3 (100 %) | NR | 2/2 (100 %) | NR | 10/10 (100 %) | NR | 3/3 (100 %) | NR | NR | |
Zitsman et al. [40] | Baseline N (%) | 35/85 (41.2 %) | 49/85 (57.6 %) | NR | NR | NR | NR | 28/85 (32.9 %) | 26/85 (31 %)†¥ | NR |
Resolved, N (%) | 8/35 (22.9 %) | 24/49 (49 %) | NR | NR | NR | NR | 4/28 (14.3 %) | 21/26 (81 %)†¥ | NR | |
RYGB | ||||||||||
Miyano et al. [51] | Baseline N (%) | 18 (29 %) | 38 (62 %) | 8 (13 %) | NR | 46 (69 %) | NR | 11 (21 %) | 11 (24 %) ¥ | 15 (27 %) |
Resolved, N (%) | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
Inge et al. [42] | Baseline N (%) | NR | NR | 1/10 (10 %) | NR | 1/10 (10 %) | NR | NR | NR | NR |
Resolved, N (%) | NR | NR | 1/1 (100 %) | NR | 1/1 (100 %) | NR | NR | NR | NR | |
Lee et al. [34] | Baseline N (%) | 6/32 | 2/32 (6 %) | 3/32 (%) | NR | 5/32 | NR | NR | NR | NR |
Resolved, N (%) | NR | 2/2 (100 %)‡ | 3/3 (100 %) | NR | NR | NR | NR | NR | NR | |
Messiah et al. [36] | Baseline N (%) | 118 (26 %) | 65 (14 %) | 67 (15 %) | NR | 117 (26 %) | 162 (36 %) ¥ 127 (28 %) # | 94 (21 %) | 85 (18 %) † 41 (9 %) ¥ | 127 (28 %) |
Improved N (%) | 61 % | 59 % | 79 % | NR | 56 % | 50 % ¥ 44 % # | 40 % | 38 % † 31 % ¥ | 62 % | |
Nijhawan et al. [44] | Baseline N (%) | 3/25 (12 %) | 10/25 (40 %) | 3/25 (12 %) | NR | 4/25 (16 %) | 14/25 (56 %)† | 6/25 (24 %) | NR | 5/25 (20 %) |
Resolved, N (%) | 3/3 (100 %) | 10/10 (100 %) | 3/3 (100 %) | NR | 4/4 (100 %) | 13/14 (92.9 %)† | 6/6 (100 %) | NR | 4/5 (80 %) | |
Olbers et al. [22] | Baseline N (%) | 0/81 (0 %) | 15/80 (19 %)†; 27/81 (33 %)◊ | 1/81 (1.2 %) | 17/78 (21 %)¥; 55/78 (70 %)‡ | 0/81 (0 %) | NR | NR | NR | NR |
Resolved, N (%) | N/A | 14/15 (93.3 %)†; 15/27 (55.5 %)◊ | 1/1 (100 %) | 13/17 (76.5 %)¥; 53/55 (96 %)‡ | N/A | NR | NR | NR | NR | |
Strauss et al. [45] | Baseline N (%) | 3/10 (30 %) | NR | NR | NR | 2/10 (20 %) | 1/10 (10 %)◊ | NR | NR | NR |
Resolved/improved, N (%) | 3/3 (100 %) | NR | NR | NR | 2/2 (100 %) | 1/1 (100 %)◊ | NR | NR | NR | |
Sugerman et al. [19] | Baseline N (%) | 11/33 (33 %) | NR | 2/33 (6 %) | NR | 6/33(18 %) | 11/33 (33 %) | NR | NR | 5/33 (15 %) |
Resolved, N (%) | 9/11 (82 %) | NR | 2/2 (100 %) | NR | 6/6 (100 %) | 4/11 (36 %) | NR | NR | 3/5 (60 %) | |
LSG | ||||||||||
Aldaqal et al. [23] | Baseline N (%) | 4/32 (13 %) | NR | 5/32 (16 %) | NR | 1/32 (3 %) | NR | NR | NR | NR |
Resolved, N (%) | 3/4 (75 %) | NR | 4/5 (80 %) | NR | 1/1 (100 %) | NR | NR | NR | NR | |
Alqahtani et al. [47] | Baseline N (%) | 39/108 (36.1 %) | 52/108 (48.1 %) | 22/108 (20.4 %) | 14/108 (13 %)¥ or ◊ | 36/108 (33.3 %) | NR | NR | NR | NR |
Resolved, N (%) | 27/36 (75 %) | 21/30 (70 %) | 15/16 (93.8 %) | 11/11 (100 %)¥ or ◊ | 20/22 (90.9 %) | NR | NR | NR | NR | |
Boza et al. [48] | Baseline N (%) | 4/51 (7.8 %) | 12/51 (23.5 %) | 2/51 (3.9 %) | 27/51 (52.9 %)† | NR | 3/51 (5.9 %)† | NR | NR | NR |
Resolved, N (%) | 4/4 (100 %) | 7/12 (58 %) | 1/2 (50 %) | 26/27 (96.2 %)† | NR | N/A | NR | NR | NR | |
Nadler et al. [57] | Baseline N (%) | 1/7 (14.3 %) | NR | NR | 3/7 (%)† | 4/7 (57 %) | 1/7 (14.3 %)§ | 1/7 (14.3 %) | 1/7 (14.3 %)¥ | 1/7 (14.3 %) |
Resolved, N (%) | 1/1 (100 %) | NR | NR | 3/3 (100 %)† | 4/4 (100 %) | 1/1 (100 %)§ | 1/1 (100 %) | 1/1 (100 %)¥ improved | 1/1 (100 %) improved |